Background/Aims The histologic status of the immune-tolerant (IT) phase of chronic hepatitis B relative to long-term outcomes is unclear. This study aimed to discover how the serological criteria currently in use correspond to histologic criteria in determining the IT phase and indication for liver biopsy.
Methods Patients in the serological IT phase determined by positive hepatitis B e antigen, hepatitis B virus (HBV) DNA ≥106 IU/mL, and normal or minimally elevated alanine aminotransferase (ALT) ≤60 IU/L, who underwent liver biopsy at three different hospitals were included. The distribution of the histologic IT phase, defined as fibrosis of stage 1 or less and inflammation of grade 1 or less, was compared with that of the serological IT phase. The risk factors for the incidence of liver-related events, such as hepatocellular carcinoma, liver cirrhosis, liver transplantation, and death, were also analyzed.
Result s: Eighty-two (31.7%) out of 259 clinically suspected IT phase patients belonged to the histologic IT phase. Age over 35, high AST, and low albumin were useful for ruling out the histologic IT phase. Risk factors predicting liver-related events were age and significant fibrosis stage. There was no significant difference in the proportion of histologic IT phase and clinical prognosis between normal ALT and mildly elevated ALT groups. However, even in patients with normal ALT, age was an important factor in predicting the presence of the histologic IT phase.
Conclusions A significant number of patients who belonged to the serological IT phase were not in the histologic IT phase. Patients over 35 years and those with high AST, low albumin, and low HBV DNA levels were more likely to experience poor long-term clinical outcomes. Therefore, additional histologic assessment should be considered.
Citations
Citations to this article as recorded by
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients Tai-Chung Tseng, Tetsuya Hosaka, Mei-Hung Pan, Chun-Jen Liu, Fumitaka Suzuki, Chien-Jen Chen, Tung-Hung Su, Hiromitsu Kumada, Wan-Ting Yang, Hung-Chih Yang, Chen-Hua Liu, Pei-Jer Chen, Hwai-I. Yang, Jia-Horng Kao Hepatology.2026; 83(1): 142. CrossRef
Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy–Induced HBsAg Seroclearance Han Ah. Lee, Hyun Woong Lee, Yeon Seok Seo, Dong Hyun Sinn, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim Journal of Gastroenterology and Hepatology.2025; 40(7): 1675. CrossRef
Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani Health Science Reports.2025;[Epub] CrossRef
Cost‐Effectiveness of Antiviral Therapy in Patients With High Viremic Indeterminate Phase Chronic Hepatitis B Suk‐Chan Jang, Won‐Mook Choi, Gi‐Ae Kim, Gwang Hyeon Choi, Yun Bin Lee, Dong Hyun Sinn, Hye‐Lin Kim, Young‐Suk Lim Liver International.2025;[Epub] CrossRef
Comparison of the efficacy and action mechanism of Chinese patent medicines for liver fibrosis and cirrhosis Lingping Fu, Jin Xie, ZeXin Wang, Tao Jiang, Yi Zeng, Jing Yan, Rong Sun, Mengshuang Huang, Shengyi Du, Xiaobao Wang, Yuyang Liu, Kailai Xi, Ailin Chen, Xiao Ma, Jinhao Zeng, Thomas Efferth Phytomedicine.2025; 148: 157246. CrossRef
Longitudinal observation of chronic domestic cat hepadnavirus infection in cats with evidence of extrahepatic involvement Sabrina Wahyu Wardhani, Sitthichok Lacharoje, Tanit Kasantikul, Chutchai Piewbang, Somporn Techangamsuwan Journal of Feline Medicine and Surgery.2025;[Epub] CrossRef
Should Indications for Antiviral Therapy for Hepatitis B Be Broadened to Include Immune-Tolerant Patients, Inactive Carriers, or Patients in the “Gray Zone”? Yen-Chun Liu, Wen-Juei Jeng Current Hepatology Reports.2024; 23(1): 11. CrossRef
Stat3 activation-triggered transcriptional networks govern the early stage of HBV-induced hepatic inflammation Jinglin Tang, Jiaxuan Zhang, Gaoli Zhang, Wenhui Peng, Ning Ling, Yingzhi Zhou, Hongmei Xu, Hong Ren, Min Chen, Marthandan Mahalingam, Swati Jain mBio.2024;[Epub] CrossRef
Noninvasive Models to Assess Liver Inflammation and Fibrosis in Chronic HBV Infected Patients with Normal or Mildly Elevated Alanine Transaminase Levels: Which One Is Most Suitable? Shasha Ma, Lian Zhou, Shutao Lin, Mingna Li, Jing Luo, Lubiao Chen Diagnostics.2024; 14(5): 456. CrossRef
Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis Hyunjae Shin, Won-Mook Choi, Seung Up Kim, Yunmi Ko, Youngsu Park, Jeayeon Park, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Fabien Zoulim JHEP Reports.2024; 6(7): 101089. CrossRef
Inverse relationship between HBV DNA levels and liver histopathological changes in immune‐tolerant CHB patients Deliang Huang, Huiyi Lai, Zhibin Zhu, Hong Yu, Jinghan Peng, Yuanyuan Chen, Xuejiao Liao, Jun Chen Journal of Viral Hepatitis.2024; 31(7): 363. CrossRef
Editorial: High qHBsAg—is it a good or bad signal? Beom Kyung Kim Alimentary Pharmacology & Therapeutics.2024; 59(12): 1616. CrossRef
Lower HBV DNA level is associated with more severe liver fibrosis in HBeAg-positive chronic hepatitis B with normal alanine transaminase Jian Wang, Li Zhu, Zhiyi Zhang, Shaoqiu Zhang, Yifan Pan, Yuanyuan Li, Fei Cao, Chao Jiang, Tao Fan, Ye Xiong, Jiacheng Liu, Yuxin Chen, Shengxia Yin, Xin Tong, Chuanwu Zhu, Xingxiang Liu, Jie Li, Chao Wu, Rui Huang Virology Journal.2024;[Epub] CrossRef
Estimating the key outcomes and hepatocellular carcinoma risk in patients in immune‐tolerant phase of chronic hepatitis B virus infection: A systematic review and meta‐analysis Min Liu, Taixue Zhao, Jinyang Zhang, Bing Bu, Ruyi Zhang, Xueshan Xia, Jiawei Geng Reviews in Medical Virology.2024;[Epub] CrossRef
Significant liver histological change is common in HBeAg-positive chronic hepatitis B with normal ALT Menghui Duan, Huanming Xiao, Meijie Shi, Yubao Xie, Pengtao Zhao, Sheng Li, Xiaoling Chi, Xueen Liu, Hui Zhuang BMC Infectious Diseases.2024;[Epub] CrossRef
Preface Seung Up Kim Clinical and Molecular Hepatology.2024; 30(Suppl): S3. CrossRef
Vibration-controlled transient elastography for significant fibrosis in treatment-naïve chronic hepatitis B patients: A systematic review and meta-analysis Mi Na Kim, Jihyun An, Eun Hwa Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Young-Joo Jin, Young Eun Chon, Seung Up Kim, Dae Won Jun, Ji Won Han, Miyoung Choi Clinical and Molecular Hepatology.2024; 30(Suppl): S106. CrossRef
HBeAg-positive CHB patients with indeterminate phase associated with a high risk of significant fibrosis Yuanyuan Li, Yijia Zhu, Dongmei Gao, Yifan Pan, Jian Wang, Shaoqiu Zhang, Xiaomin Yan, Li Zhu, Chuanwu Zhu, Xingxiang Liu, Zhaoping Zhang, Jie Li, Yuxin Chen, Rui Huang, Chao Wu Virology Journal.2024;[Epub] CrossRef
Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B? Joo Hyun Oh, Dong Hyun Sinn Clinical and Molecular Hepatology.2023; 29(2): 367. CrossRef
Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase” Chia-Ming Chu, Yun-Fan Liaw Clinical and Molecular Hepatology.2023; 29(2): 510. CrossRef
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise Moon Haeng Hur, Jeong-Hoon Lee Clinical and Molecular Hepatology.2023; 29(2): 363. CrossRef
Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase” Jeong-Ju Yoo, Sang Gyune Kim Clinical and Molecular Hepatology.2023; 29(2): 513. CrossRef
Research Progress in Histological Features and Related Influencing Factors of Chronic Hepatitis B Patients with Persistent Normal ALT 宇行 刘 Advances in Clinical Medicine.2023; 13(05): 8702. CrossRef
Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim Clinical and Molecular Hepatology.2023; 29(3): 779. CrossRef
First
Prev
